Apart from HBOC, the germline BRCA1/2 mutations have also been found in a variety of other cancers, including pancreatic cancer [3], lung cancer [4], urothelial carcinoma [5] and esophageal cancer [6], etc. It is reasonable to expect that PARPi may also be effective for these patients. Here, BRCA1 is linked to urothelial carcinoma.